The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Tight junctions in inflammatory bowel diseases and inflammatory bowel disease associated colorectal cancer
Open accessAbstract
Inflammatory bowel diseases are characterised by inflammation that compromises the integrity of the epithelial barrier. The intestinal epithelium is not only a static barrier but has evolved complex mechanisms to control and regulate bacterial interactions with the mucosal surface. Apical tight junction proteins are critical in the maintenance of epithelial barrier function and control of paracellular permeability. The characterisation of alterations in tight junction proteins as key players in epithelial barrier function in inflammatory bowel diseases is rapidly enhancing our understanding of critical mechanisms in disease pathogenesis as well as novel therapeutic opportunities. Here we give an overview of recent literature focusing on the role of tight junction proteins, in particular claudins, in inflammatory bowel diseases and inflammatory bowel disease associated colorectal cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dysregulated expression of sealing claudins and increased intestinal permeability contributes to a leaky epithelial barrier and may lead to intestinal infection and bowel symptoms of IBD patients [178,189].”
From Insights of Endocytosis Signaling in Health and Disease (2023) · cites this paper as [189]
In the citing paper
“The endocytosis of TJs and AJs happens similar to the internalization of luminal antigens into the enterocytes, and IBD patients have an increased ability to transcytosis of luminal antigens [189].”
From Insights of Endocytosis Signaling in Health and Disease (2023) · cites this paper as [189]
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L., Schreiber, S., Colombel, J., Rachmilewitz, D., Wolf, D. C., Olson, A. D., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,164
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P. J., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A. D., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,910
Inflammatory bowel disease: cause and immunobiology
Baumgart, D. C., & Carding, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60750-8 · Cited by 2,147
Intestinal barrier function: molecular regulation and disease pathogenesis
Groschwitz, K. R., & Hogan, S. P. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.05.038 · Cited by 1,775
Adherens and tight junctions: Structure, function and connections to the actin cytoskeleton
Hartsock, A., & Nelson, W. J. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.07.012 · Cited by 1,637
Claudin-based tight junctions are crucial for the mammalian epidermal barrier
Furuse, M., Hata, M., Furuse, K., Yoshida, Y., Haratake, A., Sugitani, Y., Noda, T., Kubo, A., & Tsukita, S. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200110122 · Cited by 1,512
Anderson, C., Boucher, G., Lees, C., Franke, A., D'Amato, M., Taylor, K., Lee, J., Goyette, P., Imieliński, M., Latiano, A., et al. (2011) · Nature Genetics · doi:10.1038/ng.764 · Cited by 1,361
Adenoma–linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth
Grivennikov, S. I., Wang, K., Mucida, D., Stewart, C. A., Schnabl, B., Jauch, D., Taniguchi, K., Yu, G.-Y., Österreicher, C. H., Hung, K. E., et al. (2012) · Nature · doi:10.1038/nature11465 · Cited by 1,327
Heller, F., Florian, P., Bojarski, C., Richter, J. F., Christ, M., Hillenbrand, B., Mankertz, J., Gitter, A. H., Bürgel, N., Fromm, M., et al. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.002 · Cited by 1,232
Zeißig, S., Bürgel, N., Günzel, D., Richter, J. F., Mankertz, J., Wahnschaffe, U., Kroesen, A. J., Zeitz, M., Fromm, M., & Schulzke, J. (2006) · Gut · doi:10.1136/gut.2006.094375 · Cited by 1,218
Cited by
Sorted by citations
Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway
Singh, R., Chandrashekharappa, S., Bodduluri, S. R., Baby, B. V., Hegde, B., Kotla, N. G., Hiwale, A. A., Saiyed, T., Patel, P., Vijay-Kumar, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07859-7 · Cited by 713
The intestinal barrier: a pivotal role in health, inflammation, and cancer
Neurath, M. F., Artis, D., & Becker, C. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00390-x · Cited by 593
IL-1β and the Intestinal Epithelial Tight Junction Barrier
Kaminsky, L. W., Al–Sadi, R., & Ma, T. Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.767456 · Cited by 456
Yu, L. C. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0483-8 · Cited by 419
Fructose stimulated de novo lipogenesis is promoted by inflammation
Todoric, J., Di Caro, G., Reibe, S., Henstridge, D. C., Green, C. R., Vrbanac, A., Ceteci, F., Conche, C., McNulty, R., Shalapour, S., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0261-2 · Cited by 328
Metadata
- Authors
- Landy, J., Ronde, E., English, N., Clark, S. K., Hart, A. L., Knight, S. C., Ciclitira, P. J., & Al-Hassi, H. O.
- Affiliations
- St Mark's Hospital (GB)
- St Thomas' Hospital (GB)
- Corresponding author
- Ciclitira, Paul J
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2016
- Volume
- 22
- Issue
- 11
- Pages
- 3117
- ISSN
- 1007-9327 (ISSN-L)
- PMC
- PMC4789987
- OpenAlex
- W2330707041
- Cited by
- 507
- References
- 103
- Citations by year
- 2026: 38 · 2025: 56 · 2024: 65 · 2023: 60 · 2022: 65 · 2021: 69 · 2020: 49 · 2019: 39 · 2018: 39 · 2017: 20 · 2016: 7
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- World Journal of Gastroenterology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion, other-oa)
- Funders
- Biotechnology and Biological Sciences Research Council
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
- Keywords
- tight junctions, inflammatory bowel disease, inflammatory bowel disease-associated colorectal cancer, claudins, intestinal epithelial barrier, paracellular permeability, intestinal inflammation, pathogenesis
- MeSH terms
- Animals, Anti-Inflammatory Agents, Colitis, Ulcerative, Colon, Crohn Disease, Humans, Intestinal Mucosa, Permeability, Colorectal Neoplasms, Inflammation Mediators, Tight Junctions, Pouchitis, Claudins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
